BACKGROUND Significant changes in the pathophysiology of older critically ill patients may affect the pharmacokinetics and pharmacodynamics of teicoplanin. This study aimed to determine the optimal teicoplanin blood level in this patient population. METHODS 128 older critically ill and 86 older non-critically ill patients were involved and analyzed. RESULTS The target thresholds of teicoplanin blood concentrations in older critically ill patients and non-critically ill patients should be 31.4mg/L and 15.3mg/L, respectively. The dose of teicoplanin in older critically ill patients should be greater than 800 mg to achieve the target blood level. CONCLUSION An individualized dosing approach of teicoplanin based on therapeutic drug monitoring is necessary for older critically ill patients.

中文翻译：

---

老年重症患者需要更高的替考拉宁血药浓度。

背景 老年危重患者病理生理的显着变化可能影响替考拉宁的药代动力学和药效学。本研究旨在确定该患者人群中的最佳替考拉宁血药浓度。方法对128名老年危重患者和86名老年非危重患者进行分析。结果老年重症患者和非重症患者替考拉宁血药浓度的目标阈值分别为31.4mg/L和15.3mg/L。老年危重患者的替考拉宁剂量应大于 800 mg，以达到目标血药浓度。结论 基于治疗药物监测的替考拉宁个体化给药方法对于老年危重患者是必要的。